Aridanin Attenuates Behavior Deficits and Neuroinflammatory Response in 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson’s Disease in Mice

Abstract

Background: Parkinson’s disease (PD), the second most prevalent neurological illness, is treated with pharmacologic and nonpharmacologic techniques, including medicinal plants and their extracts.Purpose: We assessed the anti-neurodegenerative properties of aridanin against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride (MPTP)-induced PD in mice.Materials and Methods: In the current investigation, the neuroprotective potential of aridanin in the MPTP-induced PD animal model via behavioral analysis, oxidative stress, pro-inflammatory cytokines, and histopathology was determined.Results: The results showed that mice treated with MPTP had mobility, motor issues, and behavioral dysfunctions. When mice were challenged with MPTP, they had low antioxidant levels. The levels of malondialdehyde (MDA) and pro-inflammatory cytokines were high in MPTP-treated mice. There are signs of PD based on these results. Behavioral effects were improved, antioxidant levels increased, and MDA and proinflammatory cytokines levels decreased in animals treated with aridanin.Conclusion: Thus, in combination, aridanin therapy guards against MPTP-induced neuronal loss, neuroinflammation, oxidative stress, and motor dysfunction in PD mice.

Keywords: Parkinson’s disease; aridanin; 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine hydrochloride; antioxidants